S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   327.93 (-0.05%)
AAPL   142.86 (-0.04%)
MSFT   231.13 (+0.70%)
FB   279.09 (+0.39%)
GOOGL   1,884.99 (-0.49%)
AMZN   3,292.69 (-0.04%)
TSLA   884.87 (+0.46%)
NVDA   540.84 (-0.97%)
BABA   261.42 (+0.02%)
CGC   35.64 (+8.30%)
GE   11.72 (+6.64%)
MU   80.40 (-1.08%)
AMD   93.91 (-0.23%)
NIO   59.29 (-1.17%)
T   29.29 (+0.62%)
F   11.41 (+1.06%)
ACB   10.94 (+7.68%)
BA   206.41 (+1.50%)
DIS   171.24 (-0.38%)
NFLX   563.05 (+1.13%)
GILD   67.75 (-0.60%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   327.93 (-0.05%)
AAPL   142.86 (-0.04%)
MSFT   231.13 (+0.70%)
FB   279.09 (+0.39%)
GOOGL   1,884.99 (-0.49%)
AMZN   3,292.69 (-0.04%)
TSLA   884.87 (+0.46%)
NVDA   540.84 (-0.97%)
BABA   261.42 (+0.02%)
CGC   35.64 (+8.30%)
GE   11.72 (+6.64%)
MU   80.40 (-1.08%)
AMD   93.91 (-0.23%)
NIO   59.29 (-1.17%)
T   29.29 (+0.62%)
F   11.41 (+1.06%)
ACB   10.94 (+7.68%)
BA   206.41 (+1.50%)
DIS   171.24 (-0.38%)
NFLX   563.05 (+1.13%)
GILD   67.75 (-0.60%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   327.93 (-0.05%)
AAPL   142.86 (-0.04%)
MSFT   231.13 (+0.70%)
FB   279.09 (+0.39%)
GOOGL   1,884.99 (-0.49%)
AMZN   3,292.69 (-0.04%)
TSLA   884.87 (+0.46%)
NVDA   540.84 (-0.97%)
BABA   261.42 (+0.02%)
CGC   35.64 (+8.30%)
GE   11.72 (+6.64%)
MU   80.40 (-1.08%)
AMD   93.91 (-0.23%)
NIO   59.29 (-1.17%)
T   29.29 (+0.62%)
F   11.41 (+1.06%)
ACB   10.94 (+7.68%)
BA   206.41 (+1.50%)
DIS   171.24 (-0.38%)
NFLX   563.05 (+1.13%)
GILD   67.75 (-0.60%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   327.93 (-0.05%)
AAPL   142.86 (-0.04%)
MSFT   231.13 (+0.70%)
FB   279.09 (+0.39%)
GOOGL   1,884.99 (-0.49%)
AMZN   3,292.69 (-0.04%)
TSLA   884.87 (+0.46%)
NVDA   540.84 (-0.97%)
BABA   261.42 (+0.02%)
CGC   35.64 (+8.30%)
GE   11.72 (+6.64%)
MU   80.40 (-1.08%)
AMD   93.91 (-0.23%)
NIO   59.29 (-1.17%)
T   29.29 (+0.62%)
F   11.41 (+1.06%)
ACB   10.94 (+7.68%)
BA   206.41 (+1.50%)
DIS   171.24 (-0.38%)
NFLX   563.05 (+1.13%)
GILD   67.75 (-0.60%)
Log in
NASDAQ:CBMG

Cellular Biomedicine Group SEC Filings & 10K Form

$18.14
-0.10 (-0.55 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.00
Now: $18.14
$18.22
50-Day Range
$17.82
MA: $18.24
$18.55
52-Week Range
$11.48
Now: $18.14
$19.50
Volume11,422 shs
Average Volume25,635 shs
Market Capitalization$353.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35

SEC Filings

Cellular Biomedicine Group (NASDAQ:CBMG) SEC Filings

DateFilerForm TypeView
12/29/2020
3:20 PM
Cellular Biomedicine Group (Subject)
Form SC 13E3/A
12/29/2020
3:11 PM
Cellular Biomedicine Group (Filer)
Form DEFM14A
12/08/2020
5:52 AM
Cellular Biomedicine Group (Subject)
Form SC 13E3/A
12/08/2020
5:41 AM
Cellular Biomedicine Group (Filer)
Form PRER14A
12/04/2020
6:30 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/17/2020
3:14 PM
Cellular Biomedicine Group (Subject)
Form SC 13E3/A
11/17/2020
3:11 PM
Cellular Biomedicine Group (Filer)
Form PRER14A
10/26/2020
6:04 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2020
6:16 AM
Cellular Biomedicine Group (Subject)
Form SC 13E3
10/09/2020
5:42 AM
Cellular Biomedicine Group (Filer)
Form PREM14A
08/28/2020
6:32 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2020
3:32 PM
Cellular Biomedicine Group (Issuer)
NOVARTIS AG (Reporting)
NOVARTIS PHARMA AG (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/12/2020
3:17 PM
Cellular Biomedicine Group (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2020
10:16 AM
Cellular Biomedicine Group (Subject)
Dangdai International Group Co. Ltd (Filed by)
Form SC 13D/A
08/12/2020
7:51 AM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D/A
08/12/2020
6:02 AM
Cellular Biomedicine Group (Filer)
Form DEFA14A
08/12/2020
5:56 AM
Cellular Biomedicine Group (Filer)
Form DEFA14A
08/12/2020
5:54 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/10/2020
3:15 PM
Cellular Biomedicine Group (Filer)
Form NT 10-Q
07/13/2020
6:32 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/29/2020
8:00 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2020
3:38 PM
Cellular Biomedicine Group (Subject)
HILLHOUSE CAPITAL ADVISORS, LTD. (Filed by)
Form SC 13D/A
06/24/2020
3:35 PM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D/A
06/22/2020
8:15 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2020
5:07 AM
Cellular Biomedicine Group (Filer)
Form DEFR14A
04/29/2020
4:19 PM
Cellular Biomedicine Group (Filer)
Form DEFA14A
04/29/2020
4:19 PM
Cellular Biomedicine Group (Filer)
Form DEF 14A
04/01/2020
8:39 AM
Cellular Biomedicine Group (Subject)
Sailing Capital Overseas Investments Fund, LP (Filed by)
Form SC 13D/A
04/01/2020
8:37 AM
Cellular Biomedicine Group (Subject)
TF Venture Capital Management Co., Ltd. (Filed by)
Form SC 13D/A
04/01/2020
8:33 AM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D/A
03/31/2020
9:16 AM
Cellular Biomedicine Group (Subject)
Dangdai International Group Co. Ltd (Filed by)
Form SC 13D/A
02/24/2020
12:50 PM
Cellular Biomedicine Group (Subject)
Dangdai International Group Co. Ltd (Filed by)
Form SC 13D/A
02/24/2020
7:00 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/21/2020
3:05 PM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D/A
02/13/2020
4:23 PM
Cellular Biomedicine Group (Issuer)
Chan Andrew K (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/13/2020
4:20 PM
Cellular Biomedicine Group (Issuer)
Liu Tony (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/03/2020
7:07 PM
Cellular Biomedicine Group (Issuer)
Chiang Chen Hsiu-Lien (Reporting)
TF Venture Capital Management Co., Ltd. (Reporting)
Winsor Capital Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/03/2020
9:19 AM
Cellular Biomedicine Group (Subject)
TF Venture Capital Management Co., Ltd. (Filed by)
Form SC 13D
01/30/2020
8:18 AM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D/A
01/30/2020
8:17 AM
Cellular Biomedicine Group (Subject)
HILLHOUSE CAPITAL ADVISORS, LTD. (Filed by)
Form SC 13D/A
01/29/2020
4:00 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2019
7:30 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2019
5:02 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2019
8:56 PM
Cellular Biomedicine Group (Issuer)
Zhang Li Helen (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/20/2019
8:53 PM
Cellular Biomedicine Group (Issuer)
Dai Chengxiang (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/20/2019
8:50 PM
Cellular Biomedicine Group (Issuer)
HILLHOUSE CAPITAL ADVISORS, LTD. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/18/2019
8:56 PM
Cellular Biomedicine Group (Issuer)
Mission Right Ltd (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/18/2019
10:55 AM
Cellular Biomedicine Group (Subject)
Dangdal International Group Co. Ltd (Filed by)
Form SC 13D/A
11/13/2019
9:07 AM
Cellular Biomedicine Group (Subject)
Liu Tony (Filed by)
Form SC 13D
11/12/2019
8:59 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2019
7:00 AM
Cellular Biomedicine Group (Subject)
HILLHOUSE CAPITAL ADVISORS, LTD. (Filed by)
Form SC 13D
11/08/2019
6:27 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2019
3:25 PM
Cellular Biomedicine Group (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/17/2019
3:10 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2019
3:12 PM
Cellular Biomedicine Group (Issuer)
Schafer Edward T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2019
3:11 PM
Cellular Biomedicine Group (Issuer)
Schafer Edward T (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/03/2019
7:30 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/27/2019
3:15 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2019
4:01 PM
Cellular Biomedicine Group (Filer)
Form CT ORDER
09/12/2019
6:49 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2019
2:24 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2019
3:10 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2019
3:03 PM
Cellular Biomedicine Group (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/23/2019
8:07 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2019
11:15 PM
Cellular Biomedicine Group (Filer)
Form EFFECT
07/05/2019
3:12 PM
Cellular Biomedicine Group (Filer)
Form S-3
Registration statement under Securities Act of 1933  
07/03/2019
4:09 PM
Cellular Biomedicine Group (Filer)
Form 424B3
07/01/2019
4:25 PM
Cellular Biomedicine Group (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/17/2019
7:23 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/16/2019
4:20 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2019
4:01 PM
Cellular Biomedicine Group (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2019
8:27 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2019
8:44 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2019
8:24 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/28/2019
10:33 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/22/2019
8:31 PM
Cellular Biomedicine Group (Filer)
Form 424B5
03/22/2019
4:29 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2019
3:20 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2019
3:11 PM
Cellular Biomedicine Group (Filer)
Form 424B5
03/15/2019
4:13 PM
Cellular Biomedicine Group (Filer)
Form DEFA14A
03/15/2019
4:11 PM
Cellular Biomedicine Group (Filer)
Form DEF 14A
03/01/2019
10:05 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/19/2019
4:01 PM
Cellular Biomedicine Group (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2019
8:53 PM
Cellular Biomedicine Group (Issuer)
Chan Andrew K (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/14/2019
8:50 PM
Cellular Biomedicine Group (Issuer)
Liu Tony (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
02/14/2019
8:48 PM
Cellular Biomedicine Group (Issuer)
Yao Yihong (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/25/2019
3:45 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/17/2019
5:30 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2019
7:00 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/28/2018
3:11 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2018
1:10 PM
Cellular Biomedicine Group (Subject)
Dangdal International Group Co. Ltd (Filed by)
Form SC 13D/A
11/06/2018
5:26 AM
Cellular Biomedicine Group (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/29/2018
7:07 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2018
8:16 AM
Cellular Biomedicine Group (Filer)
Form 424B3
10/22/2018
11:15 PM
Cellular Biomedicine Group (Filer)
Form EFFECT
10/18/2018
3:13 PM
Cellular Biomedicine Group (Filer)
Form CT ORDER
10/18/2018
3:06 PM
Cellular Biomedicine Group (Filer)
Form CT ORDER
10/10/2018
6:11 PM
Cellular Biomedicine Group (Filer)
Form S-3
Registration statement under Securities Act of 1933  
10/10/2018
7:30 AM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2018
4:27 PM
Cellular Biomedicine Group (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.